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Introduction
Inflammation processes are complex biochemical phe-
nomena that are characterized physiologically in tissues
by edema, pain, and leukocyte infiltration (1). Currently,
the most effective anti-inflammatory drugs are gluco-
corticoids. Glucocorticoids induce many proteins, such
as lipocortins. Lipocortins are inhibitors of phospholi-
pase A2 (PLA2; International Union of Biochemistry and
Molecular Biology enzyme no. 3.1.1.4 [EC 3.1.1.4]) (2, 3).
PLA2 plays a key role in the pathogenesis of allergic con-
junctivitis (4). In the inflammation process, PLA2
hydrolyzes the acyl-ester bond at the sn-2 position of
phosphoglycerides (5). This is the first rate-limiting step
in the eicosanoid cascade, generating arachidonic acid.
Arachidonic acid is converted to prostaglandins and
leukotrienes that cause inflammation (6). Therefore, an
effective treatment of inflammatory diseases is inhibition
of PLA2, blocking both cyclooxygenase and lipoxygenase
pathways in the arachidonic acid cascade (6). Steroidal
anti-inflammatory drugs inhibit PLA2 by inducing PLA2-
inhibitory proteins, including uteroglobins (a subfamily
of secretoglobins) (7) and lipocortin-1 (annexin I) (3, 8).
Miele et al. identified a region of sequence similarity
between uteroglobin and lipocortin-1 (9). Further, they
designed several synthetic peptides corresponding to
the region of highest similarity between uteroglobin
and lipocortin-1. The most effective anti-inflammato-
ry nonapeptides, termed antiflammins (AFs) by Miele
et al. (9), corresponded to uteroglobin residues 39–47
and lipocortin-1 residues 246–254. Both peptides were
shown to be PLA2 inhibitors in vitro and were effective
in a classic model of acute inflammation in carra-
geenan-induced rat footpad edema (9).
Interestingly, treatment of purified PLA2 with transg-
lutaminase 2 (TGase 2; EC 2.3.2.13) strikingly increased
PLA2 activity in vitro. TGase 2–catalyzed conforma-
tional changes in PLA2 can be brought about by forma-
tion of an intramolecular ε-(γ-glutamyl)-lysine cross-
link (10) or by incorporation of polyamines (11). These
observations suggest that TGase 2–mediated modifica-
tion may activate PLA2 in vivo, following an influx of
calcium. TGase 2 is a calcium-dependent enzyme that
catalyzes the covalent cross-linking of the γ-carboxam-
ide groups of a peptide-bound glutamine residue with
the ε-amino group of a peptide-bound lysine residue
(12). Several physiological roles for TGase 2 have been
demonstrated, such as wound healing (13), fibrosis (14),
apoptosis (15), and matrix formation (16). Increased
TGase 2 expression has been reported to occur in many
inflammatory diseases, such as celiac disease (17),
Crohn disease (18), and sporadic inclusion-body myosi-
tis (19). Pathological roles of TGase 2 in those diseases
might be associated with activation of PLA2.
Therefore we hypothesize here that blocking both
TGase 2 and PLA2 activities may ameliorate PLA2-medi-
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ated inflammation. To test this hypothesis, a series of
new recombinant peptides using sequences from AFs
and pro-elafin (cementoin) were constructed as compet-
itive inhibitors of PLA2 and TGase 2, respectively.
Cementoin is a good TGase 2 substrate for anchoring
pro-elafin onto matrix proteins (20). Further, it has been
demonstrated that sequences derived from pro-elafin
serve as competitive reversible TGase inhibitors (21).
Here we show that recombinant peptides inhibit PLA2 as
well as TGase 2. We also show that the recombinant pep-
tides abolish the TGase 2–catalyzed activation of PLA2
in vitro and have a pronounced anti-inflammatory effect
on allergic conjunctivitis in vivo.
Methods
Construction of synthetic peptides. Four peptides (A1–A4)
were synthesized based on published sequences of AFs
from lipocortin-5 (A1), lipocortin-1 (A2), uteroglobins
(A3), and the conserved region of AFs (A4) (9, 22).
Three peptides (E1–E3) were synthesized based on the
pro-elafin sequences (21, 23). Two recombinant pep-
tide sequences (R1 and R2) were constructed by com-
bining AFs and pro-elafin sequences. E1–E3 and R1–R2
peptides encoded putative TGase 2 substrate domains
that will compete with other TGase 2 substrates (21,
23). Two synthetic peptide inhibitors of PLA2 (P1 and
P2) were tested for their effectiveness as positive con-
trols (24, 25). All the peptides were synthesized and
purified by HPLC, and the compositions and concen-
trations were determined accurately by amino acid
analysis (Peptron Co., Taejun, Republic of Korea). All
peptides were dissolved in a small volume of PBS (6.7
mM phosphate, 150 mM NaCl [pH 7.3]) and stored
frozen until used.
Inhibitory effect of synthetic peptides on PLA2 in vitro.
Using an established assay, we determined the enzy-
matic activity of PLA2 by measuring the release of
[14C]arachidonic acid from 1-acyl-2-[1-14C]arachidon-
ic acid-glycerophosphoethanolamine (26). To deter-
mine the inhibitory activity, 0.18 U of PLA2 (bovine
pancreas, EC 3.1.1.4; Sigma-Aldrich, St. Louis, Mis-
souri) was preincubated for 15 minutes with the syn-
thetic peptides (1 × 10–8 M) at 37°C in 60 µl of assay
buffer (75 mM Tris-Cl, pH 9.0, 5 mM CaCl2, 1 mg/ml
fatty acid–free bovine serum albumin) before adding
1-acyl-2-[1-14C]arachidonic acid–glycerophospho-
ethanolamine. 1.0 U of PLA2 will hydrolyze 1.0 µmol of
L-α-phosphatidylcholine to L-α-lysophosphatidyl-
choline and a fatty acid per min. at pH 8.0 at 37°C.
The control was PLA2 preincubated with buffer. After
preincubation, PLA2 activity was assayed using soni-
cated liposomes, prepared as described (27). Forty
microliters of 1-acyl-2-[1-14C]arachidonic acid-glycero-
phosphoethanolamine (about 2 × 105 disintegrations
per minute) was added to the preincubated mixture
and incubated for 1 hour at 37°C. The reaction was
terminated by addition of 0.75 ml of Dole’s reagent
(78% [vol/vol] n-heptane, 20% [vol/vol] propan-2-ol,
and 2% [vol/vol] 2 M aqueous H2SO4). To extract the
liberated [14C]arachidonic acid, 0.25 ml of H2O was
added to the incubated mixture, vortexed, and cen-
trifuged at 1,200 g for 5 minutes. The upper phase was
then transferred to a tube that contained 100 mg of
silica gel (230–400 mesh; Sigma-Aldrich) and 0.75 ml
of n-heptane. The sample was vortexed and cen-
trifuged at 1,200 g for 5 minutes. The supernatant was
collected for scintillation counting. Values are the
means of three determinations (SD < 10%). For stud-
ies of the inhibitory peptides, each value is the mean of
three separate experiments (SD < 10%).
Inhibitory effect of synthetic peptides on TGase 2 in vitro. We
determined TGase activity by measuring the incorpo-
ration of [1,4-14C]putrescine into succinylated casein
(12). To determine the inhibitory effects of the pep-
tides, we preincubated 1 × 10–3 U guinea pig liver TGase
2 (EC 2.3.2.13; Sigma-Aldrich) — 1.0 U of which will
catalyze the formation of 1.0 µmol of hydroxamate per
minute from N-α-CBZ-Gln-Gly and hydroxylamine at
pH 6.0 at 37°C — for 15 minutes with the synthetic
peptides (1 × 10–8 M) in 0.1 ml of buffer containing 0.1
M Tris-acetate (pH 7.5) at 37°C. We then added the
TGase/peptide mixture to 0.5 ml of the substrate solu-
tion, containing 0.1 M Tris-acetate (pH 7.5), 1% (wt/vol)
succinylated casein, 1 mM EDTA, 10 mM CaCl2, 0.5%
(wt/vol) lubrol PX, 5 mM DTT, 0.15 M NaCl, and 0.5
mCi [1,4-14C] putrescine dihydrochloride (118 Ci/mol;
NEN Life Science Product Inc., Boston, Massachusetts,
USA). Following incubation at 37°C for 1 hour, the
reaction was terminated by addition of 4.5 ml of cold
7.5% (wt/vol) trichloroacetic acid (TCA; 4°C). The TCA-
insoluble precipitates were collected onto GF/A (Milli-
pore, Bedford, Massachusetts, USA) glass fiber filters,
washed with cold 5% (wt/vol) TCA, dried, and counted.
The control was TGase preincubated with buffer only.
Values are the means of three determinations.
Inhibitory effect of synthetic peptides on the activation of
PLA2 by TGase 2 in vitro. The synthetic peptides (1 × 10–8
M) were preincubated with 1 × 10–3 U of TGase 2 and
1.8 × 10–3 U of PLA2 in 60 µl of assay buffer for 15 min-
utes at 37°C. A negative control was incubated in the
absence of TGase, and TGase incubated in the absence
of peptides was used as a positive control. After prein-
cubation, 40 µl of 1-acyl-2-[1-14C]arachidonic acid-glyc-
erophosphoethanolamine (about 2 × 105 disintegra-
tions per minute) was added to the preincubated
mixture, and the assay mixture was incubated for 1
hour at 37°C. The reaction was terminated by addition
of 0.75 ml of Dole’s reagent, and the released arachi-
donic acid was determined as described above.
In vivo experimental model of allergic conjunctivitis.
Female guinea pigs of the Hartley strain were selected
as in previous reports (e.g., ref. 28). Eighty-six female
Hartley guinea pigs (200–250 g) were housed in the ani-
mal facilities of the Asan Institute for Life Sciences
(Republic of Korea), given guinea pig chow and water
ad libitum, and cared for in accordance with the Dec-
laration of Helsinki and the NIH Guide for the Care
and Use of Laboratory Animals (Republic of Korea).
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Giant ragweed pollen (Ambrosia trifida, 1.0–1.5 mg;
Sigma-Aldrich) was delivered once a day into the nos-
trils and the inferior conjunctival fornices of 84 ani-
mals on days 1–5 and 8–12 with a micropipette cali-
brated to 10 µl. On day 15, immunized guinea pigs
were divided into 14 groups, with six in each group.
Eleven synthetic peptides, including the new recom-
binants described here, dexamethasone eye drops
(Maxidex, 0.1% dexamethasone; Alcon-Couvreur,
Puurs, Belgium), and antihistamine eye drops (Livostin,
levocabastine; Janssen Pharmaceutica, Beerse, Bel-
gium), were used for 13 groups, and no treatment was
used for one group. Normal controls were six nonim-
munized, untreated guinea pigs. All immunized guinea
pigs were challenged with 1.0–1.5 mg of ragweed-pollen
powder delivered to the inferior conjunctival fornice on
day 15. All the procedures conformed to the experi-
mental model of allergic conjunctivitis described by
Merayo-Lloves et al. (28). All synthetic peptides were
dissolved in sterile saline (100 µmol/40 µl concentra-
tion). All peptides and dexamethasone eye solutions
were administered 3 hours before the last pollen appli-
cation on day 15, 10 minutes after pollen application,
and four times thereafter at 3-hour intervals.
Clinical evaluation for anti-inflammatory activity. Con-
junctival edema and redness were judged in room light
and under an operating microscope (Carl Zeiss,
Oberkochen, Germany). The evaluation was performed
in a blinded fashion at 20 minutes after allergen chal-
lenge. Each clinical parameter was scored on a scale of
0 to 4+ (0 absent, 1+ minimal, 2+ mild, 3+ moderate, 4+
severe) as described previously (Table 1) (28). Clinical
scores of each group (12 eyes per group) were analyzed.
Histology for anti-inflammatory activity. The orbits were
exenterated after the animals were killed with CO2
asphyxia, and lower eyelids including inferior fornicial
conjunctiva were prepared for the light-microscopic
examination. The central part of each specimen was
cut sagittally and stained with hematoxylin and eosin.
The eosinophils in standardized fields of conjunctival
epithelium, immediate subepithelium, and stroma
were counted in three nonconsecutive fields for each
treatment in each experiment (magnification ×400; 12
eyes per group).
Inhibitory effect of synthetic peptides on TGase and PLA2
activities in vivo. Inferior fornicial and palpebral con-
junctiva including conjunctival epithelium and subep-
ithelial stroma were dissected and homogenized by
means of a Sonic Dismembranator (Fisher Scientific
Co., Pittsburgh, Pennsylvania, USA) in a tenfold vol-
ume of ice-cold 0.1 M Tris-acetate (pH 7.5) and 1 mM
EDTA, containing 1% (vol/vol) Triton X-100 and pro-
tease cocktail. The homogenates were centrifuged at
10,000 g for 30 minutes at 4°C. The supernatant was
used for analysis of TGase and PLA2 activities. The
assay conditions for TGase and PLA2 were the same as
those used for in vitro assays as described above.
Results
The effect of the 11 synthesized peptides on PLA2
activity is shown in Figure 1a. The PLA2 activity in the
absence of peptides was assigned a value of 100% (5.57
pmol arachidonyl per hour). AFs (A1–A3) inhibited
PLA2 activity by about 40%, while P1 and P2 did not
significantly inhibit it (Figure 1a). Pro-elafin peptides
(E1–E3) inhibited PLA2 activity by as much as 25%
(Figure 1a). The recombinant peptide (R2) designed
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Table 1
Scale for 0-to-4+ evaluation of clinical signs in experimental conjunctivitis 
Clinical signs None (0+) Minimal (1+) Mild (2+) Moderate (3+) Severe (4+)
Conjunctival redness Absent Minimal redness Easily detectable redness Obvious redness Diffuse redness
Conjunctival edema Absent Minimal edema Focal-area chemosis Obvious chemosis Severe edema
Figure 1
The effects of various peptides on (a) PLA2 activity and (b) TGase 2
activity. (a) Purified PLA2 was preincubated with the peptides for
15 minutes before assay. The recombinant peptide R2 showed the
best inhibitory effect on PLA2 activity, although most AFs (A1–A3)
inhibited PLA2 activity to some extent. (b) Purified TGase 2 was
preincubated with the peptides for 15 minutes before assay. The
recombinant peptide R2 showed the best inhibitory effect on TGase
2 activity, although all pro-elafin peptides (E1–E3) inhibited TGase
2 activity to some extent. Data are presented as mean ± SD from
three separate experiments.
from the core domains of AF and pro-elafin inhibited
about 75% of PLA2 activity (Figure 1a). To determine
the inhibitory effect of the synthetic peptides on puri-
fied TGase 2, the enzyme was preincubated with syn-
thetic peptides in vitro at room temperature for 15
minutes before the TGase assay was started. The activ-
ity of TGase 2 incubated without peptides was
assigned a value of 100% (4.89 pmol putrescine per
hour) (Figure 1b). Pro-elafin peptides (E1–E3) inhibit-
ed TGase 2 by 40–50% (Figure 1b). P1, P2, and A1–A4
inhibited TGase 2 by about 20–40% (Figure 1b). R2
inhibited TGase 2 activity by about 70% and PLA2
activity by about 75%. R1 inhibited TGase 2 activity by
about 55%, although it did not significantly inhibit
PLA2 activity (Figure 1a).
PLA2 activity was increased by incubation with TGase
2 in vitro as previously reported (19). As the amount of
TGase 2 in the mixture was increased, PLA2 activity
increased up to twofold (Figure 2a). The increased PLA2
activity by TGase 2 was assigned a value of 100% (11.2
pmol arachidonyl per hour). R2 inhibited about 80% of
the total PLA2 activity increased by TGase 2, while AFs
(A1–A4) inhibited about 50% of the total PLA2 activity
increased by TGase 2. The effect of R2 might be due to
a combined inhibition of TGase 2 and PLA2 activities
(Figure 2b). As shown in Figures 1 and 2, R2 signifi-
cantly reduced the PLA2 and TGase 2 activities in com-
parison with the peptides known to be PLA2 inhibitors.
The effect of the synthetic peptides on the guinea pig
allergic conjunctivitis model was determined. In addi-
tion to the same set of peptides used in Figures 1 and
2, dexamethasone and Livostin were employed as pos-
itive controls. Clinical evaluation of anti-inflammato-
ry activity was based on the degree of conjunctival
edema and redness (see Methods). AFs (A1–A4) and
pro-elafin peptides (E1–E3) reduced the clinical inflam-
matory scores by 10–40% (Figure 3a). R2 reduced the
clinical inflammation score by about 50%. This reduc-
tion is almost the same as that noted with dexametha-
sone and Livostin eye drops (Figure 3a; Table 2). We
performed histological evaluation by counting eosino-
phils in the standardized fields of conjunctival epithe-
lium and subepithelial stroma. Interestingly, most pep-
tides, including AFs, Rs, and Es, reduced eosinophil
infiltration (Figure 3b). R2 and E2 provided the best
protection against inflammation (90% and 85% reduc-
tion, respectively) — even better than that shown by
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Figure 2
The effects of various peptides on activation of PLA2 by TGase 2. (a)
Purified PLA2 was preincubated with different amounts of TGase 2
for 15 minutes before assay. PLA2 activity was increased by incuba-
tion with TGase 2 in a dose-dependent manner. Data are presented
as mean ± SD from three repeats of each TGase 2 concentration. (b)
Purified PLA2 was preincubated with the peptides and 1 × 10–3 U
TGase 2 for 15 minutes before assay. The recombinant peptide R2
markedly decreased PLA2 activity, although most AFs (A1–A3) and
E3 inhibited PLA2 activity. Data are presented as mean ± SD from
three separate experiments.
Figure 3
The effects of various peptides on the conjunctival allergic reaction
in guinea pigs. (a) The recombinant peptide R2 reduced clinical aller-
gic signs as much as dexamethasone and Livostin eye drops did. The
data are the means of 12 eyes in each group. P values are in Table 2.
(b) Eosinophils in the standardized fields of conjunctival epithelium
and subepithelial stroma were counted. The recombinant peptide R2
and one peptide of the elafin series (E2) reduced eosinophil infiltra-
tion better than dexamethasone and Livostin did. Data are present-
ed as mean of 12 eyes in each group. P values are in the Table 3.
dexamethasone and Livostin (Figure 3b; Table 3). Fig-
ure 4 shows the histochemical staining pattern of
eosinophil infiltration and epithelial edema after treat-
ment with R2, E2, dexamethasone, and Livostin. The
inhibitory effect of synthetic peptides on TGase and
PLA2 activities in vivo is shown in Figure 5. The activi-
ties of TGase and PLA2 in the control were 43.2
pmol/mg/h and 26.4 nmol/mg/h, respectively. After
induction of allergy, PLA2 activity increased fivefold,
and TGase activity increased twofold. Treatment with
recombinant peptides R2 and E2 reduced activities of
TGase and PLA2 (Figure 5, a and b). Dexamethasone
and Livostin treatment resulted in a decrease of PLA2
activity, but not of TGase activity. We have repeated the
in vivo experiments (Figures 3–5) and have obtained
the same pattern of results (data not shown).
Discussion
Numerous studies have revealed that steroidal anti-
inflammatory effects are mediated by the induction of
lipocortins (3) and uteroglobins (8), which contain a
conserved nonapeptide (AF). Although Hope et al. (29)
reported that AFs have no inhibitory effect on PLA2
and no anti-inflammatory activity in vivo, we con-
firmed the findings of others (9, 30, 31) that the AFs
do indeed have inhibitory activity on PLA2 in vitro and
have anti-inflammatory effects on allergic conjunc-
tivitis in vivo (Figure 1). We also confirmed the previ-
ous finding (10) that TGase 2 increases PLA2 activity
in vitro (Figure 2). Therefore, we hypothesized that
blocking both TGase 2 and PLA2 activities might pro-
vide maximal protection against inflammation. To
test this hypothesis, we constructed recombinant pep-
tides from human lipocortin-1 and pro-elafin as com-
petitive reversible TGase inhibitors (21). These pep-
tides contain Q and/or K residue substrates of the
intact proteins. The recombinant peptide R2 showed
the greatest inhibitory effect both on TGase 2 and on
PLA2 activities in vitro, accompanied by the best anti-
inflammatory score in vivo.
Interestingly, AF-derived KVLD itself did not inhibit
PLA2 activity unless extra amino acids were added to the
sequence (Figure 1a). Further, we found that, in addi-
tion to inhibiting PLA2, AFs also had some inhibitory
activity on TGase 2 in vitro (Figure 1b). This inhibition
might be due to the lysine residue of the AFs acting as
an acyl acceptor during TGase 2 catalysis and thereby
competing with TGase 2 substrates. Analysis of AF pep-
tide sequences showed that AFs contain KVLD whereas
pro-elafin contains a similar but reversed sequence
(DPVK) (23). Cementoin (see below) is known to be a
strong TGase substrate. Therefore, AFs containing the
KVLD sequence may be dual-functional competitive
inhibitors of TGase 2 and PLA2 in vivo. R2 contains glu-
tamine and lysine residues as acyl donor and acceptor
for TGase catalysis, which might generate synergistic
inhibitory effects on TGase 2. PLA2 is a large superfam-
ily of distinct enzymes whose products are important
for signaling processes, eicosanoid and platelet-activat-
ing factor formation, membrane remodeling, and gen-
eral lipid metabolism. The PLA2 family is classified into
ten groups, including calcium-dependent PLA2 (sPLA2)
and calcium-independent PLA2 (iPLA2), by, e.g., size,
secretion characteristics, disulfide content, and molec-
ular characteristics. It should be noted that we tested
only bovine pancreas PLA2 (sPLA2 group 1) in the in
vitro inhibition assay, as did others (9, 22). At present,
we cannot predict what effects our peptides will have on
other members of the PLA2 family.
The structure of pro-elafin consists of two function-
ally unique domains; one is a TGase substrate (cemen-
toin, amino acids 23–60) and the other is a proteinase
inhibitor (amino acids 61–117). The cementoin
domain consists of five repeats of VKGQDP that serve
as both acyl donor (Q) and acceptor (K) for TGase. This
repeat was confirmed to be a very good TGase substrate
(19, 20). We found similar repeats, such as MKGQDS
in guinea pig seminal vesicle protein (SVP-1) (32) and
the reversed sequence of EPCQPKVP in human small
proline-rich protein (SPR) (33), that are known to be
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Table 2
Statistical evaluation of clinical scores shown in Figure 3a
Name Sequence P value compared with:
No treatment Dexamethasone Livostin
P1 RKLMEI 0.009 0.001 0.003
P2 GTLAKKLT 0.279 0.000 0.000
A1 SHLRKVFDK 0.003 0.007 0.009
A2 HDMNKVLDL 0.382 0.002 0.003
A3 MQMKKVLDS 0.000 0.089 0.043
A4 KVLD 0.082 0.000 0.000
R1 KVLDPVKG 0.965 0.000 0.000
R2 KVLDGQDP 0.000 0.796 0.515
E1 PVKG 0.001 0.017 0.012
E2 DPVKG 0.000 0.050 0.039
E3 GQDP 0.016 0.000 0.002
Dexamethasone 0.000
n = 12; Mann-Whitney test.
Table 3
Statistical evaluation of eosinophil count shown in Figure 3b
Name Sequence P value compared with:
No treatment Dexamethasone Livostin
P1 RKLMEI 0.002 0.000 0.000
P2 GTLAKKLT 0.004 0.000 0.000
A1 SHLRKVFDK 0.000 0.004 0.006
A2 HDMNKVLDL 0.161 0.000 0.000
A3 MQMKKVLDS 0.007 0.000 0.000
A4 KVLD 0.001 0.028 0.045
R1 KVLDPVKG 0.002 0.001 0.002
R2 KVLDGQDP 0.000 0.001A 0.002A
E1 PVKG 0.002 0.000 0.000
E2 DPVKG 0.000 0.028 0.060
E3 GQDP 0.001 0.007 0.000
Dexamethasone 0.000
n = 12; Mann-Whitney test. ABetter than dexamethasone and Livostin.
good TGase substrates. Therefore, we adopted the
sequences of PVKG and GQDP from cementoin to con-
struct recombinant peptides R1 and R2 using the
KVLD core sequence of AFs. In accord with our hypoth-
esis, the recombinant peptide containing GQDP (R2)
resulted in the best TGase inhibition in vitro and the
best anti-inflammatory score in vivo.
TGase 2 is involved in regulating the physiological
roles of pro-elafin, uteroglobin, and lipocortin (34–40).
Pro-elafin was first discovered in keratinocytes from
hyperproliferative human epidermis, such as psoriatic
epidermis. However, subsequent research revealed that
pro-elafin is a cornified cell envelope component in
normal skin (34). Once inflammation activates mono-
cytes (polymorphonuclear cells), an active form of
elafin (amino acids 61–117) is released by proteolysis
and protects tissues from damage by elastase and pro-
teinase-3 (23). The cementoin peptides remaining in
the matrix may have anti-inflammatory effects via com-
peting TGase substrates. The short peptides GQDP
and PVKG, derived from cementoin, have previously
been demonstrated to be inhibitors of cornified cell
envelope formation (21). Uteroglobin was first discov-
ered as a progesterone-induced protein that suppress-
es sperm antigenicity (35). TGase is involved as a key
modulator in modifying the surface of spermatozoa
with uteroglobin (36). Therefore, uteroglobin can com-
pete with other TGase substrates, such as PLA2.
Lipocortin-1 (annexin I) was discovered as a major glu-
cocorticoid-induced protein (37). Most lipocortins
behave as extrinsic membrane proteins, which bind
reversibly to phospholipid membranes in a manner
that depends on calcium ions. Also, during epithelial
cell differentiation, annexin I (lipocortin-1) becomes
incorporated into the cornified cell envelope via cross-
linking by TGase and cannot be extracted by SDS (38).
In buccal epithelium, annexin I constitutes about 10%
of the total barrier envelope proteins, as established by
protein sequencing (39). A recent study showed that
expression of annexin I is increased at the border
between involved and noninvolved skin in psoriasis vul-
garis (40). Thus, annexin I itself is involved in the bar-
rier formation as a major building block and possibly
also contains an anti-inflammatory function.
Many reports have shown an increase of TGase activ-
ity in diseases associated with inflammation. These dis-
eases include celiac disease (17), Crohn disease (18), and
sporadic inclusion-body myositis (19). An increase of
TGase 2 activity in these diseases might be associated
with important physiological regulation such as activa-
tion of PLA2. However, the mechanism for aberrant
TGase 2 expression is not yet clear. In the inflammato-
ry region, local cytokine levels are changed. Eosinophils
are not only the source of cytotoxic and proinflamma-
tory mediators but can also generate cytokines and
growth factors, including IL-4, IL-5, and IL-10 as Th2
cytokines, and IFN-γ as a Th1 cytokine (41). Inflamma-
tory cytokines such as IFN-γ can increase the expression
of TGase 2 in small-intestinal cells (42). Consequently,
an increase of TGase 2 may cause stimulation of PLA2
activity. In addition to PLA2 activation, TGase 2 is also
involved in the adhesion and migration of monocytes
(43), which suggests that TGase 2 may accelerate neu-
trophil adhesion to endothelial cells in the inflamma-
tory lesion. Therefore, a TGase 2 inhibitor might have
dual anti-inflammatory properties.
The mucous membrane of the conjunctiva in the ocu-
lar surface is continually exposed to a variety of antigens.
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Figure 4
Hematoxylin-and-eosin staining of inferior palpebral and fornicial
conjunctiva of guinea pigs. (a) Normal control. (b) Marked
eosinophilic infiltration (arrowheads) and epithelial edema induced
by ragweed pollen. (c) The recombinant peptide R2 markedly
reduced eosinophilic infiltration and epithelial edema. (d) E2 showed
mild epithelial edema with few eosinophils. (e and f) Dexamethasone
and Livostin eye drops showed minimal epithelial edema with few
eosinophils. Scale bar, 100 µm; insets show doubled magnification.
Figure 5
The effects of synthetic peptides, dexamethasone, and Livostin on
(a) TGase activity and (b) PLA2 activity in the conjunctiva. After
induction of allergy, PLA2 activity is increased fivefold, and TGase
activity is increased twofold. (a) TGase activity is decreased by treat-
ment of R2 and E2. Data are presented as mean ± SD from three
samples. (b) R2 and E2 markedly decrease PLA2 activity. These pep-
tides are as effective as dexamethasone and Livostin. Data are pre-
sented as mean ± SD from three samples.
In sensitized individuals, pollen, plant, house-dust mite,
or animal-dander allergens dissolved in the tear film
cross the conjunctival epithelium and activate substan-
tia propria mast cells, leading to inflammation in con-
junctiva, i.e., to allergic conjunctivitis (44, 45). The exper-
imental guinea pig allergy model closely resembles
human allergic conjunctivitis. The guinea pig conjunc-
tiva is more similar to that of the human than to that of
the rat or mouse (28). Short ragweed pollen was used as
an antigen to develop conjunctivitis, because it is a “nat-
ural allergen” that induces hay fever conjunctivitis in sus-
ceptible humans. The pollen was delivered to the ocular
and nasal mucosa in a powder form instead of as an
injected solution to mimic more closely the human clin-
ical picture found in hay fever rhinoconjunctivitis (28).
Toxic eosinophil proteins are present in conjunctiva,
cornea, tears, and contact lenses of patients suffering
from ocular allergy, suggesting an effector role for the
eosinophil in the ophthalmic manifestations of atopy.
The present study showed the same trend, with clinical
appearance and infiltration of eosinophils. Thus, histo-
logical evaluation provided a means for evaluating the
effectiveness of the synthesized peptides (Figure 3). AFs
and novel recombinant peptides showed antiallergic
effects similar to the in vitro inhibition of TGase 2 and
PLA2 activity of those peptides. The recombinant pep-
tide R2 was as effective as dexamethasone and antihista-
mine eye drops. Interestingly, R2 and E2 reduced
eosinophil infiltration (Figures 3b and 4). This pattern
was associated with inhibition of TGase 2 activity meas-
ured in vitro (Figure 1b) and in vivo (Figure 5). The in
vivo results (Figure 5) are consistent with the in vivo clin-
ical inflammation score and eosinophil count (Figure 3),
as well as with the in vitro PLA2 inhibitory effect of E2
and R2 (Figure 2b).
R2 was more effective than dexamethasone and anti-
histamine eye drops in lowering the histological
scores, as judged by counting of infiltrated eosino-
phils. The eosinophil infiltration was almost com-
pletely blocked by the recombinant peptide R2 (i.e., the
score was similar to that of untreated controls). The
strong protective effect of R2 may be due to a syner-
gistic inhibitory effect on PLA2 and TGase 2. Recently
other possible physiological actions of AFs in inflam-
mation have been discussed. Topical pretreatment
with AF-2 reduces plasma leakage, cell influx, edema,
and leukotriene B4 levels in acute inflammatory reac-
tion induced by the topical application of phorbol
ester (TPA, 12-O-tetradecanoylphorbol 13-acetate), but
not in that induced by topical application of arachi-
donic acid. This suggests that AFs may affect arachi-
donic acid mobilization and/or arachidonic acid
metabolism by 5-lipoxygenase (46). AFs have little
effect on LPS-stimulated expression of E-selectin and
ICAM-1 on human leukocytes and human coronary
artery endothelial cells (HCAECs). Treatment of
HCAEC cultures with AFs did not decrease neutrophil
(polymorphonuclear cell) binding to endothelial cells.
However, preincubation of polymorphonuclear cells
with AFs markedly decreased their adhesion to LPS-
activated HCAECs. This suggests that AFs may block
leukocyte trafficking in inflammation (47). AF-2 also
reduced the adhesion of human promyelocytic
leukemia cells to endothelial cells (48).
Although they have potent anti-inflammatory effects,
steroids have harmful side effects when excessive doses
are prescribed. Therefore, novel recombinant anti-
inflammatory peptides theoretically have enormous
possibilities as potent and safe antiallergic and anti-
inflammatory drugs. In conclusion, we have shown
that rationally designed recombinant peptides that
coinhibit both PLA2 and TGase 2 are potent anti-
inflammatory agents, which in some cases are as effec-
tive as dexamethasone and Livostin in reducing symp-
toms of allergic conjunctivitis.
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